The present report extends experience with the use of trimethoprim-sulfamethoxazole (TMP-
SMX) in children aged 3 months to 10 years. The regimen was TMP (200 mg)--SMX (1000 …

Abstract Trimethoprim-sulfamethoxazole (TMP-SMZ) was administered to five pediatric
patients with defined infections. The pharmacokinetics were studied by measurement of …

Five infants, seven to 17 months old, and an 11-year-old child were treated with 185 mg of
trimethoprim (TMP) plus 925 mg of sulfamethoxazole (SMZ) per m2 daily in two equal doses …

Trimethoprim-sulfamethoxazole (TMP-SMX) is an antimicrohial combination drug of a fixed
proportion of the diaminopyrimidine trimethoprim (TMP) and the sulfonamide …

Abstract Trimethoprim-sulfamethoxazole (TMP-SMZ) has traditionaIIy been employed as an
oral formulation for infections in ambulatory pediatric patients. However, therapeutic …

Intravenous TMP-SMZ was used to treat 19 infectious episodes in 18 patients ranging in age
from 3 weeks to 13 years. Thirteen patients with various soft tissue or skeletal infections …

Single oral dose trimethoprim pharmacokinetics were determined in 18 children aged 3
months to 13 years. Trimethoprim suspension was rapidly absorbed and quickly and widely …

Trimethoprim-sulfamethoxazole (TMP-SMX) has been available for worldwide therapeutic
study since 1968. During the past one and a half decades, obser-vations on therapeutic …

The pharmacokinetics of trimethoprim administered orally or intravenously were investigated
in six infants aged 1.7 months to 1.1 years. In these infants trimethoprim had a mean half life …

The pharmacokinetic parameters of sulfamethoxazole and trimethoprim were measured in
12 newborn infants of less than 3 days postnatal age, following a single or repeated …